BIOMARKER BASED PROGNOSTIC MODEL FOR PREDICTING OVERALL SURVIVAL IN PATIENTS WITH METASTATIC CLEAR CELL KIDNEY CANCER
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Feb 3, 2016
filing date -
Feb 3, 2015
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention describes a method of using a molecular prognostic signature, to predict overall survival in patients with metastatic clear cell renal cell carcinoma. The present invention also describes a method of selecting therapy and a process for patient risk stratification based on the molecular prognostic signature analysis.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully